HIMSS TV is your Insider’s Guide to everything HIMSS. We are the world’s first online broadcasting network, focused on global innovation and how information and technology are driving change in healthcare.
  Home
Marketing microtargeting: Consumer motivations found in a tube of toothpaste
AI/ML

Marketing microtargeting: Consumer motivations found in a tube of toothpaste

2:10

Renown Health increased Medicare Advantage membership 4 percent by using data, analytics and outreach to get to know its consumer.

Read More
Read Less

AI/ML - Similar Videos View more in AI/ML

5:31

Photographs provide roadmaps for cancer care

Dr. Ray Mak, associate professor of radiation oncology at Mass General Brigham, talks about FaceAge, an AI tool that reads cancer patients' facial images to help clinicians assess mortality risk and choose a course of treatment.

Photographs provide roadmaps for cancer care
Dr. Ray Mak, associate professor of radiation oncology at Mass General Brigham, talks about FaceAge, an AI tool that reads cancer patients' facial images to help clinicians assess mortality risk and choose a course of treatment.
5:31
8:14

Consumers may not understand AI's hidden costs

Author Karen Hao says users often do not know about the immense scale of AI data centers and their computing infrastructure, as well as the labor exploitation and environmental strain that accompany them.

Consumers may not understand AI's hidden costs
Author Karen Hao says users often do not know about the immense scale of AI data centers and their computing infrastructure, as well as the labor exploitation and environmental strain that accompany them.
8:14
7:13

Lack of regulation may stifle AI innovation

Peiling Yap, chief scientist at HealthAI, says that many responsible AI projects never move beyond pilot stages because weak governance and a lack of clear regulatory guardrails block safe scaling and widespread adoption.

Lack of regulation may stifle AI innovation
Peiling Yap, chief scientist at HealthAI, says that many responsible AI projects never move beyond pilot stages because weak governance and a lack of clear regulatory guardrails block safe scaling and widespread adoption.
7:13